 Adlai Nortye IPO gives old Novartis cancer drug new life. The proceeds will fund a Phase 3 test of a medicine once known as buparlisib and tested by Novartis in dozens of trials. The company sold 25 million shares at 23 apiece  a smaller offering than it had pitched in early August 